Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases — RIDER

Colorectal Cancer Liver Metastases Clinical Trial

Official title:
Regorafenib Combined With Irinotecan Drug-Eluting Beads as Third-line Treatment for Colorectal Cancer Liver Metastases: a Multicentre, Randomised Phase 3 Trial (RIDER)

Status Recruiting

Clinical Trial Summary

This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. The study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05794971
Study type	Interventional
Source	Sun Yat-sen University
Contact	Bo Zhang, M.D
Phone	86-13660397903
Email	zhangb28@mail.sysu.edu.cn
Status	Recruiting
Phase	Phase 3
Start date	June 10, 2023
Completion date	March 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05588297` - Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases	Phase 2
Active, not recruiting	`NCT04272931` - DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE	N/A
Completed	`NCT02086656` - PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES	Phase 2
Not yet recruiting	`NCT05873972` - Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient	N/A
Recruiting	`NCT05485909` - Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM	Phase 2
Active, not recruiting	`NCT03326791` - Aspirin in Colorectal Cancer Liver Metastases	Phase 2/Phase 3